Factors affecting PARP inhibitor use as maintenance treatment in platinum-sensitive recurrent ovarian cancer

被引：0
|
作者：
Valentine, Mark [1 ]
Perhanidis, Jessica [2 ]
Hawkes, Carol [2 ]
Thaker, Premal [1 ]
机构：
[1] Washington Univ, Sch Med, St Louis, MO 63110 USA
[2] GlaxoSmithKline, Waltham, MA USA
来源：
GYNECOLOGIC ONCOLOGY | 2021年 / 162卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
291
引用
收藏
页码：S158 / S158
页数：1
相关论文
共 50 条
  • [41] Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis
    Lee, Chee Khoon
    Friedlander, Michael L.
    Tjokrowidjaja, Angelina
    Ledermann, Jonathan A.
    Coleman, Robert L.
    Mirza, Mansoor R.
    Matulonis, Ursula A.
    Pujade-Lauraine, Eric
    Bloomfield, Ralph
    Goble, Sandra
    Wang, Ping
    Glasspool, Rosalind M.
    Scott, Clare L.
    CANCER, 2021, 127 (14) : 2432 - 2441
  • [42] Gemcitabine and Vinorelbine Combination in Platinum-Sensitive Recurrent Ovarian Cancer
    Ferrero, Annamaria
    Logrippo, Vilma
    Spanu, Pier Giorgio
    Fuso, Luca
    Perotto, Stefania
    Daniele, Alberto
    Zola, Paolo
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (09) : 1529 - 1534
  • [43] TEDOVA: vaccine OSE2101+/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
    Kabirian, Rayan
    Tredan, Olivier
    Marme, Frederik
    Paoletti, Xavier
    Eberst, Lauriane
    Lebreton, Coriolan
    Rouge, Thibault De La Motte
    Sabatier, Renaud
    Angelergues, Antoine
    Fabbro, Michel
    Van Gorp, Toon
    Mansi, Laura
    Gladieff, Laurence
    Kaczmarek, Emilie
    Alexandre, Jerome
    Grellety, Thomas
    Favier, Laure
    Welz, Julia
    Frenel, Jean-Sebastien
    Leary, Alexandra
    FUTURE ONCOLOGY, 2024, 20 (35) : 2699 - 2708
  • [44] Cost-Effectiveness of BRCA1 and BRCA2 Mutation Testing to Target PARP Inhibitor Use in Platinum-Sensitive Recurrent Ovarian Cancer
    Secord, Angeles Alvarez
    Barnett, Jason Cory
    Ledermann, Jonathan A.
    Peterson, Bercedis L.
    Myers, Evan R.
    Havrilesky, Laura J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) : 846 - 852
  • [45] REPEATED USE OF MAINTENANCE THERAPY OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSE OF OVARIAN CANCER
    Khokhlova, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A478 - A478
  • [46] Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer
    Friedlander, Michael
    Banerjee, Susana
    Mileshkin, Linda
    Scott, Clare
    Shannon, Catherine
    Goh, Jeffrey
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (04) : 323 - 331
  • [47] Front-line maintenance therapy for platinum-sensitive ovarian cancer: What's next PARP inhibitors?
    Gong, H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance
    Nakao, Takehiro
    Harano, Kenichi
    Wakabayashi, Masashi
    Naito, Yoichi
    Tanabe, Hiroshi
    Mukohara, Toru
    GYNECOLOGIC ONCOLOGY REPORTS, 2024, 55
  • [49] DOSE MODIFICATION FOR CHINESE PATIENTS ON NIRAPARIB MAINTENANCE TREATMENT FOR PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER: A POST HOC ANALYSIS
    Liu, Z.
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Tan, T.
    Dong, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A193 - A194
  • [50] PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
    Robert D. Morgan
    Andrew R. Clamp
    D. Gareth R. Evans
    Richard J. Edmondson
    Gordon C. Jayson
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 647 - 658
12345